GPRC5A

Across TCGA pan-cancer cohorts, GPRC5A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPRC5A data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GPRC5A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPRC5A expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where GPRC5A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.485	0.995	.003	57	view →
PDAC	DFS	Tertile	II,III,IV	0.241	0.565	.001	37	view →
CCRCC	OS	Median	All	0.659	0.957	.018	36	view →
COAD	DFS	Tertile	II,III,IV	0.908	1.000	.032	12	view →
GBM	DFS	Tertile	All	0.882	0.587	.038	3	view →
UCEC	DFS	Median	All	1.000	0.937	.023	2	view →
LSCC	DFS	Tertile	II,III,IV	0.887	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPRC5A–LUAD (DFS)

Open the LUAD breakdown →